Blaas- en urinewegentumoren
EFFORT Trial
Phase II prospective trial to evaluate the impact of 18FFDG-PET-CT in stratifying patients with primary muscle invasive bladder cancer and adapting the treatment accordingly.
- Inclusion criteria: Patients diagnosed with muscle invasive bladder cancer without distant metastasis on conventional imaging (CT chest, abdomen and pelvic MRI) and who are candidates for neoadjuvant chemotherapy and radical curative treatment.
- Local site Principal Investigator (Urology): prof. dr. Maarten Albersen
- Sub-investigator (Nuclear Medicine): prof. dr. Karolien Goffin
- Sub-investigator (Radiotherapy): prof. dr. Gert De Meerleer
- More information: dr. Loïc Baekelandt (PhD) via loic.baekelandt@uzleuven.be or 016 344722
SINCERE Registry
Effect of a single instillation of Mitomycin C on the intravesical recurrence rate after ureteroscopy for Upper Tract Urothelial Carcinoma: A prospective, multicenter registry study.
- Inclusion criteria: All patients ≥ 18 years old with clinically non-metastatic UTUC planned for URS, either as a diagnostic or as treatment, followed by a SI-MMC (or any equivalent) are eligible for this study.
- Local site Principal Investigator: dr. Carl Van Haute
- More information: NCT05731622
Blaaspijnsyndroom
Er zijn momenteel geen studies beschikbaar.
Niertumoren
Er zijn momenteel geen studies beschikbaar.
Overactieve blaas
Er zijn momenteel geen studies beschikbaar.
Penistumoren
Er zijn momenteel geen studies beschikbaar.
Prostaattumoren
ARASTEP
A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer
- Inclusion criteria: High-risk BCR after RP followed by adjuvant RT or salvage RT or after RP in participants who are unfit for adjuvant RT or salvage RT or after Primary RT. nmCSPC (adenocarcinoma) according to conventional imaging. PSADT < 12months.
- Local site Principal Investigator: prof. dr. Steven Joniau.
- Sub-investigator (Urology): dr. Alexander Giesen
- More information: NCT05794906.
Testistumoren
Er zijn momenteel geen studies beschikbaar.
Urinaire incontinentie
NEMISIS
Sacral neuromodulation as treatment for voiding dysfunction in multiple sclerosis patients.
- Inclusion criteria: Diagnosis of Multiple Sclerosis according the McDonald criteria, stable relapsing remitting MS, EDSS 0-6, storage LUTD with Urgency Frequency or Urgency Urinary Incontinence.
- Local site Principal Investigator: prof. dr. Frank Van der Aa
- Sub-investigator (Urology): dr. Lisa Moris
- More information: urologie.trial@uzleuven.be
Urinaire retentie
Er zijn momenteel geen studies beschikbaar.
Urineweg-infecties
MINUS Trial
Multicentric study on Infections of the Urinary tract after Stent removal
- Inclusion criteria: Patients, 18 years of age and older who receive a ureteral stent during any endoscopic procedure will be approached to participate in the study
- Local site Principal Investigator: dr. Carl Van Haute
- Sub-investigator (Urology): prof. dr. Ben Van Cleynenbreugel
- More information: NCT05329883
Questions
For more information, please contact trial urology.
- Email: urologie.trial@uzleuven.be
- Phone: +3216348345